Abstracts tagged "synovium and arthritis"

Abstract Number: 296 • 2019 ACR/ARP Annual Meeting
Prevalence of Elbow Arthritis in Patients with Rheumatoid Arthritis: A Prospective Ultrasound Study
Diana Vossen ¹, Valentin Schaefer², Florian Recker ³, Isabelle Geffken ⁴, Eva Matuschek ⁵ and Wolfgang Hartung ⁶, ¹Departement for Internal Medicine and Rheumatology, Rheinisches Rheumazentrum Meerbusch, St. Elisabeth-Hospital, Meerbusch, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Meerbusch, Germany, ²Medical Clinic III , Rheumatology und clinical Immunology, University Hospital Bonn, Bonn, Germany, ³1. Medical Clinic III , Rheumatology und clinical Immunology, University Hospital Bonn and 2. Department for Obstetrics and Gynecology, University Hospital Bonn, Bonn, Germany, ⁴Departement for Internal Medicine and Rheumatology, Rheinisches Rheumazentrum Meerbusch, St.Elisabeth Hospital, Düsseldorf, Germany, ⁵Department for Internal Medicine, Dreifaltigkeits-Krankenhaus Wesseling, bonn, Germany, ⁶Rheumatology und clinical Immunology, Asklepios Klinik, 93077 Bad Abbach, Bad Abbach, Germany
Background/Purpose: Musculoskeletal ultrasound is an important imaging method in the diagnosis of arthritis, especially rheumatoid arthritis (RA). The prevalence of elbow joint arthritis in RA…
Abstract Number: 2022 • 2019 ACR/ARP Annual Meeting
Analysis of Gene Expression from Systemic Lupus Erythematosus Synovium Reveals Unique Pathogenic Mechanisms
Erika Hubbard¹, Michelle Catalina ², Sarah Heuer ¹, Prathyusha Bachali ², Nicholas Geraci ³, Peter Lipsky ³ and Amrie Grammer ¹, ¹AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA, ²AMPEL BioSolutions and the RILITE Research Institute, Charlottesville, VA, ³AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Arthritis is a common manifestation of SLE and the ability of a new lupus therapy often depends on its ability to suppress joint inflammation.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].